Should Global Pharmas Focus More On Korean Partners?

Early-Stage, Innovative Assets May Stand Out

 
• By Jung Won Shin
post COVID-19
Deals May Slow On COVID-19-Related Trial Delays But Korea May Benefit • Source: Alamy

More from South Korea

More from Focus On Asia